View Discovery

Clinical Pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)


iM4TB - Innovative Medicines for Tuberculosis
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF)
Microbiotix, Inc.
GlaxoSmithKline
Global Alliance for TB Drug Development

Phase 1


Institute of Materia Medica
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Nearmedic Plus LLC
Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2


Sequella, Inc
CDC TBTC, NIAID, NIH, DHHS, Boston University
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Medecins Sans Frontieres, The Netherlands
Weill Medical College of Cornell University

Phase 3


Global Alliance for TB Drug Development
Médecins Sans Frontières France
Novartis
St. George's Hospital University of London
Global Alliance for TB Drug Development